Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor versus placebo in adults with primary sclerosing cholangitis
NL-OMON61401Phase 3Not yet recruiting
- Sponsor
- Ipsen
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Primary Sclerosing Cholangitis (PSC) comparing Elafibranor 120 mg with Placebo (2 arms). Primary endpoint: Event-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
elafibranor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NL-OMON61401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61401.